Detail for CD133+ Glioblastoma cells

Full Name

CD133+ Glioblastoma stem-like cells

Gene Name

Related Disease

  • Glioblastoma [ref.1]

Therapy Method


Temozolomide is the most commonly used chemotherapeutic agent in the therapy of GBM and is usually well-tolerated. It achieves its cytotoxic effect mainly by methylating the O6 position of guanine. Temozolomide displays its highest efficacy against tumors lacking MGMT expression.

The concomitant reduction in clonogenic ability, in the size of the CD133 population and in the growth kinetics of GBM cells indicates that BMP4 reduces the tumour-initiating cell pool of GBMs. BMP–BMPR signalling system—which controls the activity of normal brain stem cells—may also act as a key inhibitory regulator of tumour-initiating, stem-like cells from GBMs and the results also identify BMP4 as a novel, non-cytotoxic therapeutic effector, which may be used to prevent growth and recurrence of GBMs in humans.

Related Pathway/CSCs feature

  • Not Detected


  • [1] Temozolomide preferentially depletes cancer stem cells in glioblastoma.
    Beier D, Röhrl S, Pillai D R, et al. Cancer research, 2008, 68(14): 5706-5715.. [ 18632623 ]
  • [2] Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI.
    Yang, Y. P., et al. (2012). Biomaterials 33(5): 1462-1476. [ 22098779 ]
  • [3] G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells.
    Hasegawa, D., et al. (2016). Biochem Biophys Res Commun 471(1): 75-81. [ 26845351 ]
  • [4] Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells.
    Zhu, X. and G. Niedermann (2015). Oncoscience 2(5): 476-482. [ 26097880 ]

Back to top